Detection of bone and cartilage-related proteins in plasma of patients with a bone fracture using liquid chromatography-mass spectrometry by Grgurević, Lovorka et al.
  
 
    
 
Središnja medicinska knjižnica 
 
 
 
 
 
 
Grgurević, L., Maček, B., Đurđević, D., Vukičević, S. (2007) Detection of bone and 
cartilage-related proteins in plasma of patients with a bone fracture using liquid 
chromatography-mass spectrometry. International Orthopaedics, 31 (6). pp. 743-
751. 
 
 
 
The original publication is available at www.springelink.com 
http://www.springerlink.com/content/tj772r0357144281/ 
http://dx.doi.org/10.1007/s00264-007-0404-z 
 
http://medlib.mef.hr/306 
 
 
 
 
 
 
 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
 1 
Detection of bone and cartilage-related proteins in plasma of patients with a bone fracture using 
liquid chromatography-mass spectrometry 
 
Lovorka Grgurevic1, Boris Macek2, Dragan Durdevic3, and Slobodan Vukicevic1* 
 
1 Laboratory of Mineralized Tissues, School of Medicine, Zagreb, Croatia 
 
2 Max-Planck-Institute for Biochemistry, Department of Proteomics and Signal Transduction, 
Am Klopferspitz 18, 82152 Martinsried, Germany  
 
3 Clinic of Traumatology, Draskoviceva 19, Zagreb, Croatia 
  
 
 
 
 
Correspondence to: 
Slobodan Vukicevic, MD, Ph.D., Laboratory of Mineralized Tissues, School of Medicine, 
University of Zagreb, Salata 11, 10000 Zagreb, Croatia, E-mail: vukicev@mef.hr; tel: +385 1 
4566 812 
 
 
Running title: Bone and cartilage-related proteins in human plasma 
 2 
Abstract 
 
 
Following bone fracture, a large number of growth factors, cytokines, and their cognate receptors 
involved in the repair process are active at the fracture site. To determine whether they appear in 
the patients’ blood as candidate biomarkers for following the outcome of healing we analyzed in 
the plasma of 25 patients with an acute bone fracture following affinity plasma purification, SDS 
gel electrophoresis and liquid chromatography - tandem mass spectrometry (LC-MS/MS). Two 
hundred and thirteen nonredundant proteins were identified in the in-gel analysis of pooled 
plasma proteins. Gene ontology (GO) analysis indicated that a majority of detected proteins were 
of extracellular origin, whereas only a small number were of intracellular (cytosole and nucleus) 
origin. A significant proportion of detected proteins was involved in the cell growth and 
proliferation, transport and coagulation. Twelve proteins were potentially related to bone and 
cartilage metabolism, and several have not been previously identified in the plasma, including: 
TGF-β induced protein IG-H3, cartilage acidic protein 1, procollagen C proteinase enhancer 
protein and TGF-β receptor III.  
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Introduction 
 
The blood is rich with a large amount of previously unstudied molecules that could reflect the 
ongoing physiologic state of various tissues. As blood flows through most of the tissues of the 
human body the origins of plasma proteins are various. In the complex mixture of a plasma 
proteome, albumin and other carrier proteins are present in a high abundance, as well as proteins 
that originate from circulating blood cells. Almost all cells in the body communicate directly or 
indirectly with blood and upon damage or cell death tissue-specific proteins are released into the 
bloodstream. Therefore, most of potential undiscovered biomarkers will be eventually found in 
the plasma fraction, where much less abundant proteins enter the blood from the surrounding 
tissue. 
 Bone undergoes continuous turnover and remodeling consisting of bone formation and bone 
resorption, two opposite and well-balanced processes. The various bone serum and urinary 
markers are usually classified according to the metabolic process indicating low and high, 
decreased or increased bone turnover [1]. 
Following fracture, a large number of growth factors, cytokines, and their cognate receptors 
involved in bone repair are highly expressed at the fracture site in the first hours following injury. 
It is presumed that some or all of these factors initiate active repair process acting on the cells of 
the bone marrow, periosteum, and external soft tissues adjacent to the fracture site. Skeletal 
tissues are the main source of such proteins, while some are released from associated 
inflammatory cells at the site of injury [2, 10]. 
In this study we analyzed proteins as candidate biomarkers expressed in the plasma of patients 
with an acute bone fracture. The plasma proteins of patients were characterized by SDS gel 
electrophoresis and affinity purification followed by tandem mass spectrometry LC-MS/MS. 
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Following identification of proteins those associated with bone and cartilage metabolism were 
singled out and analyzed.  Some of characterized proteins have not yet been identified in the 
circulation and their presence or quantity could reflect the extent of injury and the success of the 
fracture repair.  
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Materials and methods 
 
Plasma collection 
Human blood plasma samples were supplied by the Clinic of Traumatology in Zagreb. The 
approval for the collecting samples was obtained from the institutional Ethics Committee. Blood 
samples from 25 adult humans (21-60 years of age) of both genders with a single long bone 
fracture were drawn into syringes containing 3.8% sodium citrate to form an anticoagulant-to-
blood ratio (v/v) 1:9. Plasma was obtained by centrifugation (15 min at 3000xg), and aliquots of 
each adult blood sample were pooled for the further analysis. Aliquot samples were stored at -
80°C until analysis. 
 
Affinity column purification 
Pooled plasma of patients with a single-bone fracture (80ml) was diluted 2-fold with 10 mM 
sodium phosphate buffer (pH 7), and applied to a heparin Sepharose column (Amersham 
Pharmacia Biotech), previously equilibrated with 10 mM sodium phosphate buffer (pH 7). Bound 
proteins were eluted from the column with 10 mM sodium phosphate buffer (pH 7) containing 1 
M and 2 M NaCl. Eluted fractions were precipitated with saturated ammonium sulfate (SAS) to a 
final concentration of 35%. 
 
SDS gel electrophoresis and in-gel digestion 
SDS-PAGE was run on a NuPAGE 10% Bis-Tris gel (Invitrogen, Carlsbad, USA) using MOPS 
SDS buffer system, and subsequently stained with Coomassie staining kit (NuPAGE, Invitrogen), 
as instructed by the manufacturer. After staining, each of the seven gel lanes was sliced in 12 
pieces and the corresponding pieces were combined as indicated in Figure 1. The pieces were 
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then subjected to in-gel reduction, alkylation and trypsin digestion as described previously [4]. 
Gel pieces were washed two times with acetonitrile/25 mM NH4HCO3, reduced by incubation 
with 10 mM dithiothreitol (DTT) for 45 minutes at 56ºC and carboxyamidomethylated by 
incubation in 55 mM iodoacetamide for 45 minutes at room temperature. Trypsin (Promega) was 
added to dried gel pieces (150 ng per piece, diluted in 25 mM NH4HCO3) and incubated 
overnight at 37°C. Tryptic peptides were extracted with formic acid/acetonitrile/H2O (10:20:70); 
and 100% acetonitrile, dried and resuspended in trifluoroacetic acid/acetonitrile/H20 (1:2:97) for 
MS analysis. 
 
Mass spectrometry 
Tryptic peptides were analyzed by a liquid chromatography-mass spectrometry (LC-MS). Agilent 
1100 nanoflow HPLC system (Agilent Technologies) was coupled to a LTQ-Orbitrap mass 
spectrometer (Thermo Scientific) using a nano-electrospray LC-MS interface (Proxeon 
Biosystems). Peptides were loaded on a home-made 75 µm C18 HPLC column in solvent “A” 
(0.5% acetic acid in Milli-Q water) and eluted with a 70-minute segmented linear gradient of 10-
60% solvent “B” (80% acetonitrile, 0.5% acetic acid in Milli-Q water) at a flow rate of ca. 250 
nL/min.  
Mass spectrometer was operated in the positive ion mode. Each measurement cycle consisted of a 
full MS scan acquired in the orbitrap analyzer at a resolution of 60000, and MS/MS 
fragmentation of the five most-intense ions in the linear ion trap analyzer. To further improve 
mass accuracy, the lock-mass option was used as described previously [9]. This has resulted in a 
typical peptide average absolute mass accuracy of less than 1 ppm.  
Peak lists were generated using in-house developed software (Raw2msm) [9], and searched 
against concatenated forward and reverse (“decoy”) IPI human database (version 3.13) using 
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Mascot search engine (Matrix Science). Searches were done with trypsin specificity (2 missed 
cleavages allowed), carboxyamidomethylation as fixed modification, and oxidized methionine as 
variable modification. Precursor ion and fragment ion mass tolerances were 10 ppm and 0.5 Da, 
respectively.  
Results of the database search were validated in the MSQuant software 
(http://msquant.sourceforge.net). Only peptides with a mass deviation lower than 5 ppm were 
accepted; two peptides were required for protein identification. 
Gene ontology (GO) analysis was performed using ProteinCenter software package (Proxeon 
Biosystems). 
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Results 
 
Gene ontology analysis of characterized plasma proteins 
Pooled plasma samples were subjected to heparin affinity chromatography to enrich for proteins 
specific for bone and cartilage, majority of which are known to have heparin binding domains. 
This has also partially removed highly abundant plasma proteins, such as albumin, 
immunoglobulins, transferin and haptoglobulin. Fractions of interest were collected, precipitated 
with ammonium sulphate and separated on 1D SDS-PAGE gel (Figure 1). Gel bands were 
excised, digested with trypsin and analyzed by LC-MS/MS. Peptide fragmentation spectra were 
searched against the human IPI protein database, and the results of the database search were 
validated using MSQuant software. Only peptides with a mass deviation lower than 5 ppm were 
accepted; two peptides were required for protein identification, which led to an overall false-
positive rate of less than 1% at both the peptide and the protein level.  
In total, two hundred and thirteen nonredundant proteins were identified in the in-gel analysis of 
pooled plasma proteins from patients with a single bone fracture and listed in Table 1.  
Gene ontology (GO) analysis of plasma proteins showed that a majority (63.8%) of detected 
proteins were of extracellular origin, whereas only a small number (7.5%) were of intracellular 
(cytosole and nucleus) origin. Interestingly, we also detected a relatively high number (35.2%) of 
membrane related proteins (Figure 2 A). 
According to the molecular function analysis, 37.6% of detected proteins had catalytic properties, 
18.3% were classified as signal transducers, and 13.1% as transporters (Figure 2 B). 
In terms of biological activity, a significant proportion of detected proteins were involved in the 
cell growth and proliferation (21.1%), transport (23.9%) and coagulation (13.1%) (Figure 2 C). 
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Identification of bone- and cartilage-related proteins 
From the list of detected proteins we singled out 12 proteins which could be related to bone and 
cartilage metabolism (Table 2). Among them there were proteins not previously identified in the 
plasma, like cartilage acidic protein 1 (CRTAC-1) which was identified with 28 peptides and an 
average peptide Mascot score of 53. A molecule also related to the cartilage metabolism was the 
Splice isoform A of the proteoglycan-4 or lubricin, identified with 2 peptides and an average 
peptide Mascot score of 60.  
Transforming growth factor beta receptor III was identified in the plasma for the first time with 4 
specific peptides and an average Mascot score of 44, as well as the transforming growth factor 
beta induced protein IG-H3, with 20 peptides and an average peptide Mascot score of 57.  
Among extracellular matrix proteins not previously detected in the plasma was the alpha 3 type 
VI collagen isoform 1 identified with 2 peptides and an average peptide Mascot score of 60.  
Previously identified extracellular matrix proteins of interest for bone repair included: isoform 
long of collagen alpha-1 (XVIII) chain precursor or endostatin with 5 peptides and an average 
peptide Mascot score of 36, splice isoform 2 of collagen alpha 3 (VI) chain precursor with 10 
identified peptides and an average peptide Mascot score of 62, extracellular matrix protein 1 
precursor with 57 identified peptides and an average peptide Mascot score of 54, and type IV 
collagenease precursor or matrix metalloproteinase-2 (MMP2) with 3 identified peptides and an 
average peptide Mascot score of 74 (Table 2). MMP-2 degrades extra-cellular proteins and 
disrupts the subendothelial basement membrane, thus enabling the transmigration of 
inflammatory cells. Another metalloproteinase inhibitor 1 (TIMP-1) was identified with 5 
peptides and an average peptide Mascot score of 49 (Table 2). 
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Discussion 
 
In this study we used state-of-the art proteomics techniques to characterize proteins in the plasma 
of patients with an acute bone fracture. Gene ontology showed a variety of different proteins, 
among which several have not been previously detected in the blood and could reflect the bone 
and cartilage stages of bone regeneration. Among them CRTAC-1, a glycosylated extracellular 
matrix molecule secreted by chondrocytes from the human articular cartilage. In the cell culture it 
was described as a candidate marker to distinguish the chondrocyte-like phenotype and activity 
from osteoblast-like and mesenchymal stem cells [15]. Thus its presence in the plasma of patients 
with an acute fracture could indicate the normal development and function of cartilaginous callus 
formation within the first week after the fracture and then its replacement by bone in the 
following weeks. In parallel CRTAC-1 could also indicate a concomitant joint cartilage injury 
immediately following an accident. In this way it may help distinguish between fractures with 
and without damaged joint cartilage, which would make CRTAC-1 an ideal marker for the 
various stages of the fracture repair. In the following study we need a precise time-related follow 
up of the plasma profile of CRTAC-1 in patients with a bone fracture with and without injured 
joint cartilage. 
Splice isoform A of the proteoglycan-4 is a secreted, cytoprotective glycoprotein, a product of the 
gene proteoglycan 4 and a major component of the synovial fluid participating in the boundary 
lubrication of synovial fluids [11, 12, 13]. It prevents protein deposition onto cartilage from 
synovial fluid, controls the adhesion-dependent synovial growth, and inhibits the adhesion of 
synovial cells to the cartilage surface. It is highly expressed by synoviocytes and could serve as a 
marker of their activity following injury. It has been previously identified in the plasma [5]. 
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The fracture healing process might be associated with a distinctive enzyme activity pattern at the 
fracture site, which may be reflected in their respective plasma/serum concentrations of various 
enzymes in their activity pattern. Thus, variations in the concentration of TIMP-1 and MMP-1 in 
the period following the fracture could have an important influence on the bone healing, as well 
as on other mechanisms leading to the development of a nonunion [6]. 
Discovery of circulating TßRIII was surprising since it is known that it has an essential role in the 
murine and chick development and that TßRIII knockout mice have an embryonic lethal 
phenotype. TßRIII acts as a TGF-ß co-receptor, concentrating ligand on the cell surface and 
enhancing ligand binding to the signaling TGF-ß receptor TßRII.[8]  It is well known that 
transforming growth factor ß1 (TGF-ß1) and its receptor TßRII together with extracellular matrix 
proteins osteocalcin and collagen type I have an important role in the process of fracture healing. 
This result might add TßRIII to a list of novel biomarkers for following fracture repair. Recently, 
it was shown that TßRIII has also an important function as a suppressor of breast and prostate 
cancer progression [3, 16]. The possibility of following the cancer progression by detection of 
TßRIII in plasma should be further examined, especially knowing the role of TGFβ-1 and related 
family members in the progression of tumor growth and metastasis [14]. 
TGF-β IG-H3 adhesion protein in plasma may play an important role in the cell-collagen 
interactions and binding to type I, II and IV collagens and may have an important role in the 
endochondral bone formation. It may also serve as a potential biomarker for the progression of 
successful bone healing. Additional studies will be needed to demonstrate the potential of these 
newly discovered plasma proteins as potential biomarkers for following the fracture healing and 
related disorders in humans. 
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Description of figures: 
 
Figure 1. Pooled plasma protein separation by one-dimensional SDS gel 
 
Pooled plasma of patients with a single-bone fracture was applied to a heparin Sepharose column 
(Amersham Pharmacia Biotech). Bound proteins were eluted from the column with 10 mM 
sodium phosphate buffer (pH 7) containing 1 M NaCl ( lane 4-7) and 2 M NaCl (lane 1-3), lane 8 
molecular mass marker . The numbers in the column indicate gel lanes sliced and prepared for 
MS analysis. Gel was stained with a Comassie Brilliant Blue. 
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Figure 2. Protein categorization using gene ontology (GO) component terms 
 
Total nonredundant proteins identified from pooled plasma of patients with a single bone fracture 
were compared according to the following categories: (A) subcellular localization, (B) molecular 
function and (C) biological process.  
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Table 1. Proteins identified by a tandem mass spectrometry LC-MS/MS in pooled purified plasma from patients with 
fracture 
 
IPI  
Accession  
number 
Protein name 
IPI00000137.1 N-acetylglucosamine-1-phosphotransferase subunit gamma precursor 
IPI00000138.1 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase 
IPI00000816.1 14-3-3 protein epsilon 
IPI00001753.1 Myosin-4 
IPI00002147.4 Chitinase-3-like protein 1 precursor 
IPI00003176.1 Serine protease HTRA1 precursor 
IPI00003351.2 Extracellular matrix protein 1 precursor 
IPI00003590.2 Isoform 1 of Sulfhydryl oxidase 1 precursor 
IPI00004957.1 Angiopoietin-related protein 3 precursor 
IPI00006114.4 Pigment epithelium-derived factor precursor 
IPI00006154.1 Isoform Long of Complement factor H-related protein 2 precursor 
IPI00006510.1 Tubulin beta-1 chain 
IPI00006543.2 Complement factor H-related 5 
IPI00006662.1 Apolipoprotein D precursor 
IPI00007118.1 Plasminogen activator inhibitor 1 precursor 
IPI00007199.4 Protein Z-dependent protease inhibitor precursor 
IPI00007221.1 Plasma serine protease inhibitor precursor 
IPI00007858.1 Myosin-13 
IPI00008556.1 Isoform 1 of Coagulation factor XI precursor 
IPI00009865.1 Keratin, type I cytoskeletal 10 
IPI00009920.2 Complement component C6 precursor 
IPI00010295.1 Carboxypeptidase N catalytic chain precursor 
IPI00010779.4 Tropomyosin 4 
IPI00010896.2  
IPI00011252.1 Complement component C8 alpha chain precursor 
IPI00011261.2 Complement component C8 gamma chain precursor 
IPI00011264.1 Complement factor H-related protein 1 precursor 
IPI00013004.1 Isoform 1 of Pyridoxal kinase 
IPI00016915.1 Insulin-like growth factor-binding protein 7 precursor 
IPI00017256.5 Ras suppressor protein 1 
IPI00017530.1 Ficolin-2 precursor 
IPI00011264.1 Complement factor H-related protein 1 precursor 
IPI00018219.1 Transforming growth factor-beta-induced protein ig-h3 precursor 
IPI00018305.3 Insulin-like growth factor-binding protein 3 precursor 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00019359.3 Keratin, type I cytoskeletal 9 
IPI00019579.1 Complement factor D precursor 
IPI00019580.1 Plasminogen precursor 
IPI00019581.1 Coagulation factor XII precursor 
IPI00019591.1 Isoform 1 
IPI00020091.1 Alpha-1-acid glycoprotein 2 precursor 
IPI00020996.3 Insulin-like growth factor-binding protein complex acid labile chain precursor 
IPI00021263.3  
IPI00021304.1 Keratin, type II cytoskeletal 2 epidermal 
IPI00021364.1 Properdin precursor 
IPI00021439.1 Actin, cytoplasmic 1 
IPI00021440.1  
IPI00021727.1 C4b-binding protein alpha chain precursor 
IPI00021841.1  
IPI00021842.1 Apolipoprotein E precursor 
IPI00021854.1 Apolipoprotein A-II precursor 
IPI00021885.1 Isoform 1 of Fibrinogen alpha chain precursor 
IPI00021891.5 Isoform Gamma-B of Fibrinogen gamma chain precursor 
IPI00022200.2 alpha 3 type VI collagen isoform 1 precursor 
IPI00022229.1 Apolipoprotein B-100 precursor 
IPI00022371.1 Histidine-rich glycoprotein precursor 
IPI00022391.1 Serum amyloid P-component precursor 
IPI00022392.1 Complement C1q subcomponent subunit A precursor 
IPI00022394.2 Com 
IPI00022395.1 Complement component C9 precursor 
IPI00022418.1 Isoform 1 of Fibronectin precursor 
IPI00022426.1 AMBP protein precursor 
IPI00022434.2 ALB protein 
IPI00022488.1 Hemopexin precursor 
IPI00022822.4 Isoform Long of Collagen alpha-1(XVIII) chain precursor 
IPI00022895.7 Alpha-1B-glycoprotein precursor 
IPI00022937.3 Coagulation factor V 
IPI00023006.1 Actin, alpha cardiac muscle 1 
IPI00023728.1 Gamma-glutamyl hydrolase precursor 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00024825.2 Isoform A of Proteoglycan-4 precursor 
IPI00025204.1 CD5 antigen-like precursor 
IPI00025276.1 Isoform XB of Tenascin-X precursor 
IPI00025862.1 C4b-binding 
IPI00026314.1 Isoform 1 of Gelsolin precursor 
IPI00026689.4 Hypothetical protein DKFZp686L20222 
IPI00027507.1 Complement factor H-related protein 3 precursor 
IPI00027780.1 72 kDa type IV collagenase precursor 
IPI00027827.2 Extracellular superoxide dismutase [Cu-Zn] precursor 
IPI00028091.2 Actin-like protein 3 
IPI00028413.7 Inter-alpha-trypsin inhibitor heavy chain H3 precursor 
IPI00029061.2 Selenoprotein P precursor 
IPI00029193.1 Hepatocyte growth factor activator precursor 
IPI00029236.1 Insulin-like growth factor-binding protein 5 precursor 
IPI00029739.4 Isoform 1 of Complement factor H precursor 
IPI00029863.4 Alpha-2-antiplasmin precursor 
IPI00032179.2 Antithrombin III variant 
IPI00032220.3 Angiotensinogen precursor 
IPI00032258.4  
IPI00032291.1 Complement C5 precursor 
IPI00032292.1 Metalloproteinase inhibitor 1 precursor 
IPI00032311.4 Lipopolysaccharide-binding protein precursor 
IPI00032328.1 Isoform HMW of Kininogen-1 precursor 
IPI00041065.3 Hyaluronan-binding protein 2 precursor 
IPI00043083.1 Beta-parvin 
IPI00060715.1 BTB/POZ domain-containing protein KCTD12 
IPI00154742.5 25 kDa protein 
IPI00163207.1 Isoform 1 of N-acetylmuramoyl-L-alanine amidase precursor 
IPI00164623.4 187 kDa protein 
IPI00165438.2 Muscle type neuropilin 1 
IPI00168728.1 FLJ00385 protein (Fragment) 
IPI00178083.2 29 kDa protein 
IPI00183968.4 tropomyosin 3 isoform 1 
IPI00186903.3 Isoform 2 of Apolipoprotein-L1 precursor 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00216134.3 tropomyosin 1 alpha chain isoform 7 
IPI00216699.1 Isoform 2 of Unc-112-related protein 2 
IPI00216773.4 ALB protein 
IPI00218192.2 Isoform 2 of Inter-alpha-trypsin inhibitor heavy chain H4 precursor 
IPI00218732.2 Serum paraoxonase/arylesterase 1 
IPI00219018.6 Glycer 
IPI00219465.4 Transcobalamin-2 precursor 
IPI00219682.5 Erythrocyte band 7 integral membrane protein 
IPI00219713.1 Isoform Gamma-A of Fibrinogen gamma chain precursor 
IPI00220327.2 Keratin, type II cytoskeletal 1 
IPI00220350.1 Isoform Beta-3B of Integrin beta-3 precursor 
IPI00220642.6 14-3-3 protein gamma 
IPI00220644.8 pyruvate kinase 3 isoform 2 
IPI00220701.3 Isoform 2 of Collagen alpha-3(VI) chain precursor 
IPI00289831.4 Isoform PTPS of Receptor-type tyrosine-protein phosphatase S precursor 
IPI00291262.3 Clusterin precursor 
IPI00291866.5 Plasma protease C1 inhibitor precursor 
IPI00291867.3 Complement factor I precursor 
IPI00292218.3 Hepatocyte growth factor-like protein precursor 
IPI00292530.1 Inter-alpha-trypsin inhibitor heavy chain H1 precursor 
IPI00292950.4 Heparin cofactor 2 precursor 
IPI00293925.2 Isoform 1 of Ficolin-3 precursor 
IPI00294004.1 Vitamin K-dependent protein S precursor 
IPI00294193.4 Isoform 1 of Inter-alpha-trypsin inhibitor heavy chain H4 precursor 
IPI00294395.1 Complement component C8 beta chain precursor 
IPI00295976.5 Isoform 1 of Integrin alpha-IIb precursor 
IPI00296099.6 Thrombospondin-1 precursor 
IPI00296165.5 Complement C1r subcomponent precursor 
IPI00296176.2  
IPI00296537.3 Isoform C of Fibulin-1 precursor 
IPI00296608.6 Complement component C7 precursor 
IPI00297284.1 Insulin-like growth factor-binding protein 2 precursor 
IPI00297550.7 Coagulation factor XIII A chain precursor 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00297779.6 T-complex protein 1 subunit beta 
IPI00298497.3 Fibrinogen beta chain precursor 
IPI00298828.3 Beta-2-glycoprotein 1 precursor 
IPI00298860.5 Growth-inhibiting protein 12 
IPI00298971.1 Vitronectin precursor 
IPI00298994.5 271 kDa protein 
IPI00299145.8 Keratin, type II cytoskeletal 6E 
IPI00299547.4 Neutrophil gelatinase-associate 
IPI00299738.1 Procollagen C-endopeptidase enhancer 1 precursor 
IPI00302592.2 filamin 1 
IPI00303476.1 ATP synthase subunit beta, mitochondrial precursor 
IPI00303963.1 C 
IPI00304273.2 Apolipoprotein A-IV precursor 
IPI00304865.3 transforming growth factor, beta receptor III 
IPI00305461.2 Inter-alpha-trypsin inhibitor heavy chain H2 precursor 
IPI00306311.8 Pleckstrin 
IPI00328609.3 Kallistatin precursor 
IPI00328703.1 OAF homolog 
IPI00329775.7 Isoform 1 of Carboxypeptidase B2 precursor 
IPI00333828.4 Serpin A11 precursor 
IPI00339228.1 Isoform 8 of Fibronectin precursor 
IPI00382436.1 Ig lambda chain V-III region SH 
IPI00382606.1 Factor VII active site mutant immunoconjugate 
IPI00383111.2 57 kDa protein 
IPI00384280.5 Prenylcysteine oxidase precursor 
IPI00384444.4 Keratin, type I cytoskeletal 14 
IPI00384938.1 Hypothetical protein DKFZp686N02209 
IPI00385429.1 collectin sub-family member 11 isoform b 
IPI00387025.1 Ig kappa chain V-I region DEE 
IPI00387099.1 Ig kappa chain V-I region Rei 
IPI00387113.1 Ig kappa chain V-III region B6 
IPI00387120.1 Ig kappa chain V-IV region Len 
IPI00399007.5 Hypothetical protein DKFZp686I04196 (Fragment) 
IPI00418153.1 Hypothetical protein DKFZp686I15212 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00418163.3 complement com 
IPI00418495.4 Platelet 
IPI00419424.3 IGKV1-5 protein 
IPI00426051.3 Hypothetical protein DKFZp686C15213 
IPI00430808.1 Hypothetical protein 
IPI00430842.3 IGHA1 protein 
IPI00431645.1 HP protein 
IPI00448925.3 IGHG1 protein 
IPI00451624.1 Isoform 1 of Cartilage acidic protein 1 precursor 
IPI00465248.5 enolase 1 
IPI00465378.1 Apolipoprotein A-V precursor 
IPI00465439.4  
IPI00472073.1 HLA class I histocompatibility antigen, B-59 alpha chain precursor 
IPI00472610.2 IGHM protein 
IPI00477090.5 IGHM protein 
IPI00477597.1 Isoform 1 of Haptoglobin-related protein precursor 
IPI00477644.2 26 kDa protein 
IPI00477992.1 complement component 1, q subcomponent, B chain precursor 
IPI00478003.1 Alpha-2-macroglobulin precursor 
IPI00478493.3 HP protein 
IPI00479116.1 Carboxypeptidase N subunit 2 precursor 
IPI00479708.5 IGHM protein 
IPI00549291.4 IGHM protein 
IPI00550991.3 Isoform 1 of Alpha-1-antichymotrypsin precursor 
IPI00553177.1 Alpha-1-antitrypsi 
IPI00641368.4 Tsukushi precursor 
IPI00641737.1 Haptoglobin precursor 
IPI00643034.2 Isoform 1 of Phospholipid transfer protein precursor 
IPI00643041.2 GTP-binding nuclear protein Ran 
IPI00643525.1 Complement component 4A 
IPI00646909.2 Tubulin alpha-8 chain 
IPI00654888.3 Kallikrein B, plasma (Fletcher factor) 1 
IPI00719373.1 IGLC1 protein 
IPI00745872.2 Isoform 1 of Serum albumin precursor 
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Table 1. Continued 
 
IPI  
Accession  
number 
Protein name 
IPI00783024.1 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 
IPI00783987.1 Complement C3 precursor (Fragment) 
IPI00784822.1 Hypothetical protein 
IPI00785050.1 Hypothetical protein 
IPI00785200.1 Hypothetical protein 
IPI00787629.1 similar to Apolipoprotein 
IPI00790993.1 104 kDa protein 
IPI00794487.1 Immunoblobulin light chain (Fragment) 
IPI00807531.1 IGHG1 protein 
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Table 2. 
Protein name IPI accession 
number 
Number of 
identified 
peptides 
Average 
peptides 
Mascot 
score 
Previously 
dentified in 
plasma 
GO console: 
Molecular function 
GO console: 
Cellular component 
GO console: 
Biological  Process 
Extracellular 
matrix protein 1 
precursor IPI00003351.2 57 54 + 
-Signal transducer activity 
-Structural molecule activity 
-transporter activity 
 
Extracellular -cell communication 
-metabolism 
-regulation of biological process 
-transport 
Transforming 
growth factor 
beta induced 
protein IG-H3 
precursor  
IPI 00018219.1 20 57 - 
-protein binding Extracellular -cell proliferation 
- regulation of biological process 
-sensory perception 
Splice isoform 1 
of cartilage acidic 
protein 1 
precursor  
IPI00451624.1 28 53 
- 
-metal ion binding -proteasom 
-Golgi complex 
 
Splice isoform 2 
of collagen alpha 
3 (VI) chain 
precursor 
IPI00220701.3 10 62 + 
-enzyme regulator activity 
-protein binding 
- Structural molecule activity 
Extracellular -development 
-transport 
Type IV 
collagenease 
precursor 
IPI00027780.1 3 74 + 
- catalytic activity 
- enzyme regulator activity 
- Metal ion binding - 
Extracellular -development 
-metabolism 
Alpha 3 type VI 
collagen isoform 
1 precursor 
IPI00022200.2 2 60 - 
-enzyme regulator activity 
-protein binding 
-Structural molecule activity 
Extracellular -development 
-transport 
Procollagen C 
proteinase 
enhancer protein 
precursor 
IPI00299738.1 10 58 
- 
- nucleic acid binding 
-protein binding 
Extracellular -development 
-metabolism 
Transforming 
growth factor 
beta receptor III  
IPI00304865.3 4 44 - 
-receptor activity 
-signal transducer activity 
-Golgi  -cell communication 
-development 
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Table 2. continued 
 
 
Individual peptide Mascot scores > 27 indicate identity or extensive homology (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Isoform Long of 
Collagen alpha-
1(XVIII) chain 
precursor 
IPI00022822.4 
5 36 + 
-Metal ion binding 
-protein binding 
-structural molecular activity 
Extracellular -cell death 
-cell motility 
-cell organization and biogenesis 
-cell proliferation 
-development 
-regulation of biological process 
-sensory per ception 
-transport 
Hyaluronan 
binding protein 2 
precursor 
IPI00041065.3 
7 51 + 
- catalytic activity 
 
Extracellular -metabolism 
Metalloproteinase 
inhibitor 1 
precursor 
IPI00032292.1 
5 49 + 
-catalytic activity 
-enzyme regulator activity 
-Metal ion binding 
Extracellular -cell proliferation 
-development 
-regulation of biological process 
-metabolism 
Splice isoform A 
of proteoglycan-4 
precursor  
IPI00024825.2 
2 60 + 
 Extracellular Cell proliferation 
